ZCA
TXMD icon

Zeke Capital Advisors’s TherapeuticsMD TXMD Stock Holding History

Zeke Capital Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-207
Closed -$64K – 745
2018
Q2 		$64K Hold
207
– – 0.01% 616
2018
Q1 		$50K Hold
207
– – ﹤0.01% 634
2017
Q4 		$62K Buy
+207
New +$57.6K 0.01% 548

Other funds holding TXMD

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Zeke Capital Advisors's TXMD Position: Q3 2018 in Review

Zeke Capital Advisors sold out of TherapeuticsMD (TXMD) in Q3 2018, closing a stake of 207 shares — an estimated $64K sold.

Zeke Capital Advisors first reported a position in TXMD in Q4 2017 and held it in 3 quarters. The position peaked at $64K in Q2 2018. 155 funds tracked by Wall St. Rank hold TXMD as of Q3 2018.

  • Zeke Capital Advisors reported no remaining TherapeuticsMD position as of Q3 2018 after selling out during the quarter.
  • Zeke Capital Advisors sold 207 TherapeuticsMD shares in Q3 2018, an estimated $64K.
  • Zeke Capital Advisors first reported a position in TherapeuticsMD in Q4 2017 and held it in 3 quarters.
  • Zeke Capital Advisors's TherapeuticsMD position peaked at $64K in Q2 2018.
  • 155 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2018.

Based on Zeke Capital Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.